The Role of Donor Selection for a Second Allogeneic Stem Cell Transplantation in Patients with AML Relapsing after a First Transplant; A Study on Behalf of the Acute Leukemia Working Party of EBMT
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.134
Abstract: Introduction Recurrent disease is the major cause of treatment failure after allogeneic stem cell transplantation (SCT) in patients with AML. Second SCT (SCT2) is a valid treatment option in this setting but outcome is relatively… read more here.
Keywords: sct2; haplo; transplantation; donor ... See more keywords
Post Transplant Cyclophosphamide Following Myeloablative TBI As a Conditioning Regimen for High-Risk Patients with AML Who Relapse after Transplant with Busulfan-Containing Regimen
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.399
Abstract: Introduction Allogeneic HSCT (alloHSCT) offers a potential cure for patients with AML; however, 40% of AML patients receiving alloHSCT will experience relapsed disease. Second alloHSCT can offer the best long-term survival but is associated with… read more here.
Keywords: post transplant; patients aml; busulfan containing; transplant ... See more keywords
Endothelial Activation and Stress Index (EASIX) Score at 100 Days Post-allo HCT in Patients with Acute Myeloid Leukemia Predicts Overall Survival
Sign Up to like & getrecommendations! Published in 2020 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2019.12.634
Abstract: Background Allogeneic hematopoietic stem cell transplant (HCT) is a potentially curative treatment modality for patients with AML. However, the success of transplant is limited by transplant-related mortality. Post-transplant complications have been linked to endothelial damage… read more here.
Keywords: allo hct; patients aml; hct; endothelial activation ... See more keywords
Siglec-7 is an indicator of natural killer cell function in acute myeloid leukemia.
Sign Up to like & getrecommendations! Published in 2021 at "International immunopharmacology"
DOI: 10.1016/j.intimp.2021.107965
Abstract: Immune dysfunction is an established risk factor in acute myeloid leukemia (AML). The cytotoxicity of natural killer (NK) cells is greatly impaired in AML, and the profile of NK cell receptors is markedly altered in… read more here.
Keywords: myeloid leukemia; natural killer; patients aml; acute myeloid ... See more keywords
Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML
Sign Up to like & getrecommendations! Published in 2017 at "Bone Marrow Transplantation"
DOI: 10.1038/bmt.2017.36
Abstract: For patients with AML, the best alternative donor remains to be defined. We analyze outcomes of patients who underwent myeloablative umbilical cord blood or haploidentical hemopoietic stem cell transplantation (HSCT) in Spain. Fifty-one patients underwent… read more here.
Keywords: ptcy haplo; cord; patients aml; transplantation ... See more keywords
Identifying effective drug combinations for patients with acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2020.1782749
Abstract: ABSTRACT Introduction The development of high-throughput sequencing technologies and the relentless pursuit of quality translational and clinical research allowed us to understand the leukemogenesis driven by recurrent mutations and design targeted therapies. As a result,… read more here.
Keywords: myeloid leukemia; patients aml; drug; acute myeloid ... See more keywords
Biomarkers involved in evaluation of platelets function in South-Eastern Romanian patients with hematological malignancies subtypes
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000025944
Abstract: Abstract At present, various researches presented how subtypes of hematological malignancies are related to stages of the immune response, because the activated immune system represents a promising form in cancer treatment. This study explores the… read more here.
Keywords: control subgroups; hematological malignancies; patients aml; platelet ... See more keywords
Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-3622
Abstract: Purpose: We assessed the impact of donor type in acute myeloid leukemia (AML) patients transplanted with 2 Gy total body irradiation (TBI)-based nonmyeloablative conditioning regimen. Patients and Methods: Data from 1,715 adult patients, with AML… read more here.
Keywords: impact donor; tbi based; donor type; patients aml ... See more keywords
Abstract CT085: iCare 1: A prospective clinical trial to predict treatment response based on mutanome-informed computational biology in patients with AML and MDS
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct085
Abstract: Hypomethylating agents (HMAs) (azacitidine (aza), decitabine (dec)) and lenalidomide (len) are approved agents and used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Despite their widespread use, HMAs fail in the… read more here.
Keywords: clinical trial; aml mds; response; patients aml ... See more keywords
Patients with AML Worry about More Than Just Dying: Quantifying Patient Experience Using Best-Worst Scaling
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116669
Abstract: Background: Patients with acute myeloid leukemia (AML) face poor outcomes and treatments with significant and debilitating toxicities. New regimens with improved efficacy and an improved side effect profile are needed. Documenting patient experience can assist… read more here.
Keywords: experience; treatment; patients aml; side ... See more keywords
Real-World Application of Molecular Genetic Sequencing in the Management of Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes: The Wisconsin Experience
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-123676
Abstract: Background: Next-generation sequencing (NGS) technologies have led to the discovery of recurrently-mutated genes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). These mutations have proven useful in diagnosis, prognostication, and prediction of treatment response… read more here.
Keywords: risk; aml patients; molecular data; patients mds ... See more keywords